title: [Effects of Local Radiation Combined with Chemotherapy in the treatment of  Patients with Extensive-stage Small Cell Lung Cancer].
abstract: OBJECTIVE
  Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thus can alleviate the local symptoms and improve quality of life, but limited evidence is available for prolonging survival. Hence, this study evaluated the role of local treatment in chemotherapy of patients with ES-SCLC.
  
  
  METHODS
  A total of 302 ES-SCLC cases were enrolled in this retrospective study. Prognostic factors were analyzed by Kaplan-Meier and Cox multivariate proportional hazards model.
  
  
  RESULTS
  Median progression-free survival (PFS) and median survival time (MST) of the patients were 4.4 and 10.4 months, respectively. 1-, 2-, and 3-year survival rates were 37.8%, 10.2% and 4.4%, correspondingly. The MST of the primary tumor radiotherapy plus chemotherapy group was 14.3 months, whereas that of the chemotherapy group was 8.2 months (P<0.01). The MSTs of multiple-site, single-site, and non-metastasis local treatments were 18.7, 12.3 and 8.9 months, respectively (P<0.01). The MSTs of initiative, passive, and non-metastasis local treatments were 16.0, 10.9 and 9.4 months, correspondingly (P<0.01). The MSTs of patients with prophylactic cranial irradiation (PCI) and those without PCI were 19.8 and 9.9 months, respectively (P<0.01). Primary tumor radiotherapy, metastasis local treatment, and PCI were independent prognostic factors for ES-SCLC.
  
  
  CONCLUSIONS
  Primary tumor radiotherapy, metastasis local treatment, and PCI can significantly improve survival in patients with ES-SCLC. .
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Di
authors.initials: D
authors.lastname: Wu
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Nie
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Dai
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Chen
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Weiheng
authors.initials: W
authors.lastname: Hu
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Jindi
authors.initials: J
authors.lastname: Han
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Xiangjuan
authors.initials: X
authors.lastname: Ma
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Guangming
authors.initials: G
authors.lastname: Tian
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Sen
authors.initials: S
authors.lastname: Han
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Jieran
authors.initials: J
authors.lastname: Long
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the Second Department of Chest Cancer,  Peking University Cancer Hospital and Institute, Beijing 100142, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents